PRME · Prime Medicine, Inc.

📣 What PRME Says Is Next

• in 2027 · “Prime Medicine has initiated study startup activities, with initial clinical data anticipated in 2027.”
  Company press release, Aug 6, 2026 · SEC filing
• in 2027 · “Initial clinical data from both programs are expected in 2027.”
  Company press release, Aug 6, 2026 · SEC filing
• second half of 2026 · “We expect to initiate our global Phase 1/2 study of PM577a in the second half of 2026 and to submit an IND and/or CTA for PM647 in the third quarter, with initial clinical data from both programs anticipated in 2027.”
  Company press release, Aug 6, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Dec 2026 · Phase 1 · Recruiting · A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033
  Registry primary completion date, not a results date
• Jun 2027 · N/A · Upcoming Trial · Comparison of Postoperative Sensitivity Following Bulk-Fill and Conventional Incremental C
  Registry primary completion date, not a results date
• Dec 2027 · N/A · Active Trial · Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clin
  Registry primary completion date, not a results date
• Nov 2028 · Phase 1/2 · Recruiting · A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Di
  Registry primary completion date, not a results date
• Jan 2030 · Phase 1/2 · Enrolling · A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox A
  Registry primary completion date, not a results date
• Apr 2026 · N/A · Recruiting · Comparison of Post Operative Pain in Resin-Based and Bioceramic Based Root Canal Sealers i
  Registry date passed, readout not confirmed

📊 Drug Pipeline

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRME holds $95.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $41.9M/quarter from operations, an estimated runway of 6.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

• Cash runway 7 months +30
• ATM program on file since Nov 2025 +15
• Shelf registration (S-3ASR, Nov 2025) +10
• Going-concern doubt in the latest 10-Q +15Because certain elements of management’s plans to mitigate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern are outside of the Company’s control, including the ability to raise capital through an equity or other financing, those elements cannot be considered probab 10-Q, Aug 2026
• Share count +35% in a year +14

Recent financing filings on SEC EDGAR:

• Nov 7, 2025 · Shelf registration with ATM program, up to $200M · S-3ASR
• Jul 31, 2025 · ATM program · 424B5
• Jul 30, 2025 · ATM program · 424B5
• Sep 30, 2024 · Private placement (8-K Item 3.02) · 8-K
• Feb 16, 2024 · Underwritten offering · 424B5
• Feb 14, 2024 · Underwritten offering · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRME files for a raise →

👥 Who Owns PRME

Share count 181,376,856 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.